10
2-12-92 JS①

ORNL/TM-12034

**OAK RIDGE
NATIONAL
LABORATORY**

MARTIN MARIETTA

**General Guidelines for Medically Screening
Mixed Population Groups Potentially Exposed to
Nerve or Vesicant Agents**

A. P. Watson
F. R. Sidell
S. S. Leffingwell
N. B. Munro

MANAGED BY
MARTIN MARIETTA ENERGY SYSTEMS, INC.
FOR THE UNITED STATES
DEPARTMENT OF ENERGY

This report has been reproduced directly from the best available copy.

Available to DOE and DOE contractors from the Office of Scientific and Technical Information, P.O. Box 62, Oak Ridge, TN 37831; prices available from (615) 576-8401, FTS 626-8401.

Available to the public from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Rd., Springfield, VA 22161.

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

Health and Safety Research Division

**GENERAL GUIDELINES FOR MEDICALLY SCREENING MIXED POPULATION
GROUPS POTENTIALLY EXPOSED TO NERVE OR VESICANT AGENTS**

A. P. Watson, ORNL
F. R. Sidell, USAMRICD
S. S. Leffingwell, CDC/CEHIC
N. B. Munro, ORNL

Date Published - January 1992

Prepared for the
U.S. Department of the Army
Office of the Assistant Secretary
(Installations, Logistics and Environment)
under Interagency Agreement No. 1769-1354-A1

Prepared by the
OAK RIDGE NATIONAL LABORATORY
Oak Ridge, Tennessee 37831
managed by
MARTIN MARIETTA ENERGY SYSTEMS, INC.
for the
U.S. DEPARTMENT OF ENERGY
under Contract No. DE-AC05-84OR21400

EB
MASTER

TABLE OF CONTENTS

FOREWORD	vii
ACKNOWLEDGEMENTS	ix
ABSTRACT	1
GENERAL SCREENING GUIDELINES	1
REFERENCES	7
GLOSSARY	8

LIST OF TABLES

<u>Table</u>		<u>Page</u>
1	Antidote Treatment Guidelines for Nerve and Vesicant Agent Exposure	4
2	General Decontamination Guidelines for Nerve and Vesicant Agents	6

FOREWORD

When confronted with the possibility of managing a potentially agent-exposed population, some state and local health officials have considered blood sampling for cholinesterase (ChE) activity determination in the event of a possible nerve agent exposure. Urine sampling for thiodiglycol (a metabolite of sulfur mustard) has been considered by these same health officials as a screen in the event of a possible mustard agent exposure. The brief analysis that follows has been collaboratively developed for the Chemical Stockpile Emergency Preparedness Program (CSEPP) by the authors to

- document why such population exposure screening analysis is discouraged, and
- provide alternate guidelines that have proved useful in practice

This analysis has been approved for release by the CSEPP Reentry and Restoration Subcommittee.

ACKNOWLEDGEMENTS

This analysis was sponsored by the U.S. Department of the Army, Office of the Assistant Secretary for Installations, Logistics, and Environment under Interagency Agreement DOE No. 1769-1354-A1.

A. P. Watson and N. B. Munro are employed by Martin Marietta Energy Systems, Inc., at the Oak Ridge National Laboratory, Oak Ridge, TN, managed for the U.S. Department of Energy under contract DE-AC05-84OR21400.

F. R. Sidell, M.D., is an employee of the Chemical Casualty Division of the U.S. Army Medical Research Institute of Chemical Defense at Aberdeen Proving Ground, MD.

S. S. Leffingwell, M.D., M.P.H, is an employee of the Center for Environmental Health and Injury Control, Centers for Disease Control, U.S. Public Health Service, Department of Health and Human Services, Atlanta, GA.

GENERAL GUIDELINES FOR MEDICALLY SCREENING MIXED POPULATION GROUPS POTENTIALLY EXPOSED TO NERVE OR VESICANT AGENTS

A. P. Watson, ORNL
F. R. Sidell, USAMRICD
S. S. Leffingwell, CDC/CEHIC
N. B. Munro, ORNL

ABSTRACT

A number of state and local planners have requested guidance on screening protocols and have expressed interest in sampling body fluids from exposed or potentially exposed individuals as a means of estimating agent dose. These guidelines have been developed to provide a clear statement that could be used by state and local emergency response personnel in the event of a nerve or vesicant agent incident resulting in off-post contamination; maximum protection from harm is the goal. The assumption is that any population group so exposed would be heterogeneous for age, gender, reproductive status, and state of health.

GENERAL SCREENING GUIDELINES

In all cases, emergency response and medical personnel should wear protective clothing, and take special precautions to avoid self-contamination (i.e., butyl rubber gloves and aprons, etc.), cross-contamination, or contamination of medical equipment and transport vehicles. Undiluted household bleach is particularly suited for immediate decontamination of gloves or small equipment items possessing smooth surfaces (e.g., scissors).

- 1) **Individuals exhibiting any signs/symptoms** should be immediately segregated, treated according to observed severity of toxic response (see Table 1), stripped, and decontaminated to reduce further exposure via potentially contaminated skin, hair, or clothing (see Table 2 and Sidell 1990).
- 2) **All individuals potentially exposed to liquid agent** in the form of splash, direct droplet/aerosol deposition, or skin contact with potentially contaminated surfaces should undergo decontamination and change into fresh, clean clothing.
- 3) **Special precautions for a sulfur mustard incident.** Immediate decontamination to reduce the potential for sulfur mustard exposure is imperative for several reasons:
 - a) There can be a delay of several hours' duration between exposure to sulfur mustard agents and onset of skin/eye irritation or pain.
 - b) There is no specific antidote for sulfur mustard poisoning; severity of symptoms is governed by absorbed dose.

c) Sulfur mustard agents are known human carcinogens. Any exposure poses some calculated risk of cancer induction.

4) For those individuals NOT exhibiting signs/symptoms.

a) If a vesicant agent release is involved, decontaminate any potentially exposed individual and dress him (her) out in fresh, clean clothing

b) If a nerve agent release is involved, decontaminate any potentially exposed individual and dress him/her out in fresh, clean clothing. Employ a buddy system or medical personnel to keep potentially exposed individuals under strict observation for at least 60 minutes and close observation for 24 hours. Sign or symptom levels such as "blurred vision only, pupillary constriction (with or without blurred vision) only" do not usually require treatment and will resolve without medical intervention. Most signs and/or symptoms of organophosphate poisoning will usually present within an hour after initial exposure; however, effects are well known to occur as long as 4 to 8 hours after percutaneous exposure. Some cases did not display symptoms until 18 hours post-exposure. Note that the smaller the exposure, the longer the time to symptom onset; effects that occur many hours later are usually non-lethal. If signs and/or symptoms other than those outlined immediately above develop, the exposed individual should be immediately segregated and treated with antidotes as outlined in Table 1. Upon release, asymptomatic individuals should be counseled to undergo no further exposure to OP or carbamate insecticides (e.g., rose dust, flea and tick control products for family pets, etc.) for a period of 3 to 4 weeks.

Blood and Urine Samples

We recommend emergency medical management of exposed or suspect populations on the basis of classical signs and symptoms. Determination of blood ChE activity (for nerve agents) or urine thiodiglycol (a metabolite of sulfur mustard) concentration would be best used as a diagnostic confirmation of severe exposure and as a monitor of recovery.

We do not recommend ChE activity determination as a population screen for several reasons:

1) **Lack of baseline ChE data for individuals in sample population.** Most individuals, unless they are part of a closely monitored agricultural worker group, do not have regular determinations of baseline ChE activity performed. Normal human ChE activity values represent a wide range that may be further altered by such factors as disease, reproductive and nutritional status, and drug or alcohol use. Age and gender may also be factors. Without a baseline determination on the same individual, it is impossible to sort out differences in ChE activity due to sources of biological variability vs. nerve agent exposure. Note that RBC-ChE activity is a more stable indicator of OP exposure than plasma ChE activity.

2) **Logistics.** Handling/tracking large numbers of blood samples from asymptomatic individuals would require resources that could be better utilized on more immediate emergency activities.

3) **Lab turnaround.** Large numbers of samples would generate a backlog in most labs, and data would likely not be available for several days after blood draw. This interval is too great to be of any practical assistance in diagnosis or treatment of populations during an emergency.

Depending on analytical and staffing capability, throughput rates are rarely in excess of 20/day for the Michel method. Other methods, such as the Dupont ACA, are faster and more efficient. To our knowledge, Army labs use the Michel method for human ChE determination. The availability of commercial clinical lab capability is largely location-specific and should be determined beforehand in the event that large-scale blood ChE activity determinations are expected.

4) **Analytical variability between diagnostic laboratories.** Round-robin analysis of duplicate blood samples by diagnostic labs following the same protocol can provide results that vary as much as 24% (Harlin and Ross 1990). Variability this large does not permit reliable determination of clinically significant ChE depression when data from several labs are being used.

5) **Kinetics of cholinesterase depression.** Depending on OP dose, route of exposure, and ChE assay used, ChE may not reach its minimum value for several hours. This is especially true for the red blood cell (RBC) cholinesterase (Morgan 1989). Note, however, that inhalation doses of nerve agent vapor can rapidly depress ChE activity; minimum values should be attained within 15-30 minutes post exposure.

We do not recommend urine thiodiglycol determination as a population screen for two reasons:

1) **Urine thiodiglycol monitoring as a measure of sulfur mustard exposure is an experimental technique** that is not suited for wide-scale application as a routine screen for potential exposure. It has proved useful as a recovery monitor in a recent case of occupational sulfur mustard exposure to a chemical munitions worker, wherein 24-hour urine samples were examined for a 3-4 week period. Abnormally high concentrations of thiodiglycol were observed in the worker's urine for 1 week post-exposure.

2) **Logistics of obtaining 24-hour urine samples.** To reduce the variability characterizing urinalysis that relies on single, demand samples, 24-hour urine samples for thiodiglycol determination are necessary.

Table 1. Antidote Treatment Guidelines for Nerve and Vesicant Agent Exposure^a

Nerve Agents (GA, GB, VX)	
Symptom Level	Treatment
Convulsions, coma, severe respiratory distress, muscle fasciculations (other than at site of contact).	<ul style="list-style-type: none"> • <u>6 mg atropine IM</u>. Repeat 2 mg doses IV every 5-15 minutes as needed. No IV atropine if patient hypoxic. Ventilation. Pediatric: 25-40 ug/kg. Infant: 25 ug/kg.^b • <u>1-2 gm 2-PAM-Cl (Protopam®)</u> in 100 mL saline IV over 15-30 min for initial dose with careful monitoring of blood pressure throughout infusion. Second dose after 1 h if symptoms indicate. Pediatric: 15-25 mg/kg. Infant: try 15 mg/kg. • <u>≥ 10 mg diazepam (Valium®)</u> to control seizure activity and reduce possibility of resultant brain damage. • Support respiration.
Abdominal cramping, diffuse sweating, mild respiratory hypersecretions, diarrhea.	<ul style="list-style-type: none"> • <u>2 mg atropine IM</u>. Repeat 2 mg doses IM or IV every 5-15 minutes as needed. Pediatric: 15-25 ug/kg. Infant: 15 ug/kg.^b • <u>1-2 gm 2-PAM-Cl (Protopam®)</u> in 100 mL saline IV over 15-30 min for initial dose with careful monitoring of blood pressure throughout infusion. Second dose after 1 h if symptoms indicate. Pediatric: 15-25 mg/kg. Infant: try 15 mg/kg.
Pupillary constriction (e.g., miosis), runny nose and shortness of breath	<ul style="list-style-type: none"> • <u>2 mg atropine IM</u> repeated at 5 min intervals until breathing is "comfortable." • <u>1 gm 2-PAM-Cl (Protopam®)</u> in 100 mL saline IV over 15-30 min.
Blurred vision only, pupillary constriction (e.g. miosis) (with or without blurred vision) only.	<ul style="list-style-type: none"> • Observe without treatment.

^aSee footnotes at end of table.

^bSee footnotes at end of table.

Table 1. Antidote Treatment Guidelines for Nerve and Vesicant Agent Exposure^a (Continued)

Vesicant Agents (H, HD, HT, L)	
<u>Symptom Level</u>	<u>Treatment</u>
Mustards: Chemicals burns/blisters, pulmonary distress, immunosuppression/bone marrow damage, eye damage	<ul style="list-style-type: none"> • Ventilatory support with O₂ and PEEP^c, some fluids, dark room; follow burn regimen for large blisters (do not unroof), asepsis. Do not overhydrate. No specific therapy proven in man^{d,e}
Lewisite: Chemical burns/blisters, tissue blanching, dead skin, coughing and pulmonary secretions, GI symptoms of emesis and diarrhea, eye damage. Pain.	<ul style="list-style-type: none"> • <u>BAL in oil injection</u>, 0.5 mL/25 lbs. body wt. deep IM (to max. of 4 mL). • Repeat BAL injection every 4 h to a total of 4 doses. Shorten interval to 2 h for severe cases. BAL ophthalmic ointment if eye exposure.
Mustards: Eye irritation (red eyes or photophobia); respiratory irritation; itching, reddening of skin with small blisters.	<ul style="list-style-type: none"> • <u>Antihistamines and corticosteroids</u> may relieve skin and eye irritation; protect eyes from light with dark glasses, dark room or patch(es). Guard against infections
Lewisite: Stinging pain and reddening, itching and irritation of skin. Pain, reddening and swelling of eye tissues. Small blisters.	<ul style="list-style-type: none"> • <u>BAL in oil injection</u>, 0.5 mL/25 lbs. body wt. deep IM (to max of 4 mL). Repeat as needed every 4 h; 4 doses unlikely. BAL ophthalmic ointment if eye exposure.

^aFor more detailed description of casualty therapy, see Sidell, 1990 (USAMRICD TM 90-1).

^bProvide atropine until signs of "atropinization" occur (secretions are dry and ventilation is easy; comfortable breathing in conscious patients); use until signs of improvement are observed and then taper off dose (Leffingwell, 1990; Sidell 1986, 1988, 1990).

^cPositive End-Expiratory Pressure.

^dAn experimental therapy, consisting of high doses of sodium thiosulfate (3000 mg/kg to react with mustard), Vit E (20 mg/kg to scavenge free radicals) and a corticosteroid (dexamethasone at 8 mg/kg) within 30 min after exposure permitted lab rats to survive 3 LD₅₀ of mustard (Vojvodic et al. 1985).

^eCortisone injections plus hydrocortisone ointment decreased the depth of skin injury in dermally exposed rabbits. However, this corticosteroid treatment did not speed healing (Vogt et al. 1984).

Table 2. General Decontamination Guidelines for Nerve and Vesicant Agents^a

1. For best results, VICTIM MUST BE DECONED WITHIN MINUTES OF INITIAL EXPOSURE
2. For staff, must be before exit from a "dirty" or potentially contaminated area. Mustard agents and VX are particularly problematic
3. Staff need protective equipment, clothing, etc., particularly before entry to confined space
4. Flush exposed EYES with copious quantities of water only (DO NOT USE BLEACH OR ANY OTHER DECON SOLUTION ON EYE OR ANY OTHER MUCOUS TISSUE)
5. For best results, decon skin with undiluted Clorox® (5% NaClO). This treatment will be irritating to wounds. Use copious quantities of clear water as rinse.
6. Blot (do not swab or wipe) skin with decon solution
7. In the absence of chlorine solutions, use available alkaline substance such as washing or baking soda, ammonia, etc.; or soap and lukewarm water followed by copious quantities of clear water; etc.
8. Decon clothing, instruments with high test hypochlorite [HTH, 15% Ca (ClO)₂] or Clorox® [5% (NaClO)]. SUPER TROPICAL BLEACH (STB, chlorinated lime and calcium oxide) suitable for SURFACES ONLY.
9. Dispose of potentially contaminated clothing in plastic bag(s). Twist, tape, fold over, tape again. Double-bag, remove from occupied area, and hold for disposal. Contents should be disposed of in an environmentally acceptable manner.

^aMore detailed decontamination guidelines are compiled in "Standards for Decontamination for the Chemical Stockpile Emergency Preparedness Program" by B. Shumpert and A. Watson, ORNL (Draft of September 1991 in Steering Committee review).

REFERENCES

- Harlin, K. S. and P. F. Ross (1990). "Enzymatic-spectrophotometric method for the determination of cholinesterase activity in whole blood: collaborative study." J. Assoc. Off. Anal. Chem. 73: 616-621.
- Leffingwell, S.S. (1990). "Health effects of incidents," handout and oral presentation, Technical Orientation Workshop, Landmark Inn, Park City, Utah, Sept. 5-7, 1990. Sponsored by Automation Subcommittee, Chemical Stockpile Emergency Preparedness Program.
- Morgan, D.P. (1989). *Recognition and management of pesticide poisonings*, 4th Ed. EPA-540/9-88-001. U.S. Environmental Protection Agency, Washington, DC.
- Munro, N.B., et al (1990). "Treating exposure to chemical warfare agents: implications for health care providers and community emergency planning," Environmental Health Perspectives 89: 205-215.
- Munro, N.B., et al (1991). "Cholinesterase activity levels in domestic animals as a potential biomonitor for nerve agent and other organophosphate exposure," J. Amer. Vet. Med. Assoc. 199(1): 103-115.
- Sidell, F.R. (1986). "General guidelines for therapy of acetylcholinesterase intoxication," (Course handout). Biomedical Laboratory, Medical Research Division, Aberdeen Proving Ground, MD 21010-5425.
- Sidell, F.R. (1988). "Medical aspects of nerve agent exposure," pp.3-8 In: Medical Bulletin of the U.S. Army Medical Department, PB-88-8, 7th Army Medical Command, Heidelberg, Germany.
- Sidell, F.R. (1990). "Clinical notes on chemical casualty care." Pamphlet USAMRICD TM 90-1, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010-5425.
- Van Hooideonk, C., et al. (1983). "CW agents and the skin. Penetration decontamination." pp. 153-160, in *Proc. of the International Symposium on Protection Against Chemical Warfare Agents*, Stockholm, FOA Reports C40171-C2-C3.
- Vogt, R. et al (1984). "Pathogenesis of skin lesions caused by sulfur mustard," Fundam. Appl. Toxicol. 4:571-583
- Vojvodic, V., et al. (1985). "The protective effect of different drugs in rats poisoned by sulfur and nitrogen mustards," Fundam. Appl. Toxicol. 5: S160-S168.

GLOSSARY

asepsis -- prevention of septic infection by use of sterilized dressings, instruments, etc.

atropine -- an antidote to organophosphate insecticide and nerve agent poisoning; acts by blocking stimulation from excess acetylcholine at parasympathetic receptor sites; relieves smooth muscle constriction in lung and GI tract and reduces glandular paralysis; dries up respiratory tract secretions.

BAL -- British Anti-Lewisite; the synthetic dithiol 2,3-dimercapto-1-propanol developed as a Lewisite antidote by British toxicologists in the years immediately prior to WWII. If given to victim within 1 h of exposure, can prevent skin vesication; also enhances urinary excretion of systemic arsenic resulting from Lewisite exposure.

cholinesterase (ChE) -- a normally occurring enzyme that inhibits the acetylcholine neurotransmitter found at nerve endings. Cholinesterase prevents excessive accumulation of acetylcholine, which (accumulation) results in uncontrolled impulse transmission and toxic signs such as drooling, miosis, cardiac arrhythmia, convulsions, etc. The toxicity of organophosphate compounds results from their ability to inhibit cholinesterase and permit excess quantities of acetylcholine to accumulate at synapses.

Dupont ACA -- a commercial analytical method that utilizes the colorimetric determination of thiocholine to quantify plasma cholinesterase activity. A direct method with results in U/mL; 10 min per sample.

fasciculations -- isolated areas of uncontrolled muscle twitching described by some as looking like "a bag of worms." A sign of organophosphate nerve agent exposure.

GI -- gastrointestinal (tract). When used to describe nerve agent exposure, refers to diarrhea, abdominal cramping, vomiting, etc.

kg -- kilogram (approx. 2.2 lb).

Lewisite -- an organic arsenical vesicant, dichloro(2-chlorovinyl) arsine. More volatile than the sulfur mustard agents; causes immediate severe pain upon skin or eye contact. Stockpiled only at Tooele Army Depot, Utah.

μg -- microgram, or 1 millionth of a gram (i.e., 10^{-6} g).

mg -- milligram, or 1 thousandth of a gram (i.e., 10^{-3} g).

miosis -- pupil pin-pointing, an early sign of OP exposure.

Michel method -- a once-popular analytical method for determining red blood cell cholinesterase activity. Employs the change in pH of the assay mixture as a result of the enzymatic hydrolysis of acetylcholine. An indirect method with results in $\Delta\text{pH/mL/h}$; 90 min per sample.

organophosphate (OP) -- insecticides and nerve agents that contain carbon, oxygen, and phosphorous atoms plus other moieties. All inhibit cholinesterase enzymes and result in a "short-circuit" of normal nervous system control of the muscles, some glands and the central nervous system. The result is over-stimulation and malfunction. At increasing doses, signs include pupil pin-pointing (miosis), frontal headache, abdominal cramping, diarrhea, respiratory distress, uncontrolled muscle twitching, copious respiratory secretions, convulsions and respiratory arrest. Commercial OP insecticides include malathion, diazinon, and guthion; OP nerve agents in the unitary stockpile include GA, GB, and VX. Nerve agents are approximately 10^3 to 10^4 times more potent than commercially available OP insecticides.

2-PAM-Cl -- protopam chloride; 2-pyridine aldoxime methyl chloride. An antidote to organophosphate insecticide and nerve agent poisoning; acts by removing OP from ChE and restores normal control of skeletal muscle contraction. Most effective when given with atropine.

sulfur mustard -- a group of vesicant agents (H, HD, HT) that are various formulations of bis(2-chloroethyl) sulfide. Produces skin blisters and damage to eyes and respiratory tract; human carcinogen; mutagenic in cellular assays.

vesicant -- term describing blister agents; those agents (H, HD, HT, Lewisite) that produce vesicles or blisters on skin and damage both eyes and mucous membranes.

INTERNAL DISTRIBUTION

1. M. V. Adler
2. E. D. Copenhaver
3. C. E. Easterly
4. K. S. Gant
5. S. Garrett, Jr.
6. R. N. Hamm
- 7-11. N. B. Munro (5)
12. R. M. Reed
13. B. L. Shumpert
- 14-18. J. H. Sorensen (5)
- 19-68. A. P. Watson (50)
69. Central Research Library
- 70-71. Laboratory Records, Department
72. Laboratory Records, ORNL-RC
73. ORNL-Patent Section
74. Document Reference Section

EXTERNAL DISTRIBUTION

75. Dr. James Adams, Exposure Assessment Branch (H709C), U.S. EPA Office of Pesticide Programs, 401 M St. SW, Washington, DC 20460
76. Linda W. Anderson, Center for Disease Control, Department of Health and Human Services, 1600 Clifton Road, Mail Stop F-29, Atlanta, GA 30333
77. Col. Eric Azuma, Department of the Army Headquarters SFIL-CD, Office of the Assistant Secretary of the Army (I&L), Room 1A 875, Washington, DC 20310-0130
78. Ms. Sandy Benbrook, Manager, Plans and Preparedness Unit, Washington State, 4220 E. Martin Way, Olympia, WA 98504
79. Mr. George E. Bickerton, Director, Office of Emergency Planning, Food Safety and Inspection Service, U.S. Department of Agriculture, Room 0009-South, 14th and Independence Avenue, SW, Washington, DC 20250-3700
80. Mr. Kyle Blackman, Hazardous Materials Branch, Federal Emergency Management Agency, 500 C Street, SW, Washington, DC 20472
81. Mr. Randy Cerar, USATHAMA, Installation Restoration, AMXTH-AS-D/Bldg. 4435, Aberdeen Proving Ground, MD 21010-5401

EXTERNAL DISTRIBUTION (CONTINUED)

- 82. Capt. Len Cruze, US Army, Program Manager of Chemical Demilitarization, (SAIL-PMS), Aberdeen Proving Ground, MD 21010-5401
- 83. Remley Grove, Food and Drug Administration, Room 13-64, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD 20857
- 84. Ms. Veronique Hauschild, ATTN: HSHB-ME-SE/V. Hauschild, Aberdeen Proving Ground, MD 21010-5422
- 85. Dr. Caroline Herzenberg, EAIS Division, Bldg. 331, Argonne National Laboratory, Argonne, Illinois 60439
- 86. Tom Hess, Regulatory Agency Liaison, Office of the Deputy for Chemical Demilitarization, OASA (IL&E), The Pentagon, Room 1A875, Washington, DC 20310-0110
- 87. Dr. Stephen L. Kistner, U.S. Army Environmental Hygiene Agency, ATTN: Scientific Advisor (S. L. Kistner), Aberdeen Proving Ground, MD 21010-5422
- 88. Dennis H. Kwiatkowski, Federal Emergency Management Agency, Assistant Associate Director, Office of Natural and Technological Hazards Programs, 500 C Street, SW, Room 630, Washington, DC 20472
- 89. Dr. Joseph Lafornera, US Environmental Protection Agency, 2890 Woodbridge Avenue, Bldg. 18 (MS-101), Edison, NJ 08837-3679
- 90-94. Dr. Sanford S. Leffingwell, US Public Health Service, CDC/CEHIC, Mail Stop F-29, 1600 Clifton Road, Atlanta, Georgia 30333
- 95. Linda Lewis, Argonne National Lab., 370 L'Enfant Promenade, SW, Suite 702, Washington, DC 20472
- 96. Dr. Roger McIntosh, US Army, Office of the Surgeon General, ATTN: SGPS-PSP (R. McIntosh), 5109 Leesburg Pike, Falls Church, VA 22041-3258
- 97. Maj. Leonard P. Motz, U.S. Army Materiel Command, HQ-AMC, 5001 Eisenhower Avenue, Alexandria, VA 22333

EXTERNAL DISTRIBUTION (CONTINUED)

- 98. Office of the Assistant Manger, Energy Research and Development, P. O. Box 2001, Oak Ridge, TN 37831
- 99-108. Office of Scientific and Technical Information, P. O. Box 62, Oak Ridge, TN 37831
- 109. Mr. Tim O'Dowd, Federal Emergency Management Agency, Region IV, 1371 Peachtree Street, NE, Suite 706, Atlanta, GA 30309
- 110. Ms. Elizabeth A. Peterson, c/o Commander, Headquarters, U.S. Army AMCCOM, ATTN: AMSMC-SR/B. Peterson, Rock Island, IL 61299-6000
- 111. Ms. Dianna Ricketts, Safety Engineer, Office of the Program Executive Officer, Program Manager for Chemical Demilitarization, ATTN: SAIL-PMS (Greg St. Pierre), Aberdeen Proving Ground, MD 21010-5401
- 112. Greg St. Pierre, Office of the Program Execuitve Officer, Program Manager for Chemical Demilitarization, ATTN: SAIL-PMS (G. St. Pierre), Aberdeen Proving Ground, MD 21010-5401
- 113-117. Dr. Frederick R. Sidell, 14 Brooks Road, Bel Air, MD 21014
- 118. Jim Taylor, Federal Emergency Management Agency, 500 C Street, SW, Washington, DC 20472
- 119. Phyllis Thompson, Director, CSEPP Training Management, FEMA HQ, 500 C Street, SW, Washington, DC 20472
- 120. Ms. Linda Vasta-Hughes, Federal Emergency Management Agency, 500 C Street, SW, Washington, DC 20472
- 121. Dr. J. Richard Ward, U.S. Army Chemical Research Development and Engineering Command, ATTN: SMCCR-RSC/J. Richard Ward, Aberdeen Proving Ground, MD 21010-5423
- 122. Roger Young, US Army Corps of Engineers, P. O. Box 1600, ATTN: Roger Young, CEHND-ED-CS, Huntsville, AL 35807
- 123. Kurt E. Zimmerman, Emergency Response Coordinator, Department of Environmental Quality, Division of Environmental Response and Remediation, 1950 West North Temple, Salt Lake City, UT 84114-4840

END

**DATE
FILMED**

3 / 23 / 92